{"gene":"STAT6","run_date":"2026-04-28T20:42:08","timeline":{"discoveries":[{"year":1996,"finding":"STAT6 is essential for IL-4 signaling: Stat6-deficient mice show abolished IL-4-induced B-cell proliferation, impaired T-cell proliferative responses, and loss of CD23/MHC class II upregulation, demonstrating STAT6 is the central mediator of IL-4-mediated biological responses.","method":"Gene targeting (knockout mice), functional immune assays","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 — foundational KO study with multiple orthogonal phenotypic readouts, replicated widely","pmids":["8602263"],"is_preprint":false},{"year":1996,"finding":"STAT6 is also required for IL-13 signaling in macrophages: STAT6-deficient mice show impaired IL-13-induced morphological changes, MHC class II upregulation, and failure to decrease nitric oxide production, indicating IL-4 and IL-13 share the STAT6 signaling pathway.","method":"STAT6 knockout mice, macrophage functional assays","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — clean KO with multiple defined cellular phenotypes","pmids":["8871614"],"is_preprint":false},{"year":1997,"finding":"The carboxyl terminus of STAT6 contains a 140-amino-acid proline-rich transcriptional activation domain required for IL-4-induced gene expression; truncation mutants lacking this domain cannot activate transcription and act as dominant negatives.","method":"Gal4 fusion constructs, deletion mutant analysis, reporter gene assays","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 1 — domain mapping with mutagenesis and functional reporter assays","pmids":["9233621"],"is_preprint":false},{"year":1998,"finding":"The STAT6 SH2 domain mediates both receptor binding (to tyrosine-phosphorylated IL-4Rα) and dimerization; mutational analysis identified residues specifically required for each function, and the SH2 domain structure resembles but differs from Src SH2 at C-terminal ends.","method":"Alanine-scanning mutagenesis, phosphopeptide binding assays, DNA binding assays, expression in mammalian and insect cells","journal":"Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — extensive mutational analysis with multiple functional readouts","pmids":["9651359"],"is_preprint":false},{"year":1998,"finding":"A conditionally active STAT6 fusion protein (STAT6:ER*) activates STAT6-regulated gene expression (CD23 induction, reporter activation) independently of detectable tyrosine phosphorylation, suggesting STAT6 can signal through phosphorylation-independent mechanisms.","method":"Conditional fusion protein (hormone-binding domain), reporter assays, flow cytometry","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 — single study with defined mechanistic outcome using engineered construct","pmids":["9686563"],"is_preprint":false},{"year":1999,"finding":"STAT6 interacts with the coactivator p300/CBP through its C-terminal transactivation domain; this interaction is required for IL-4-induced transcription, as E1A (which sequesters p300/CBP) blocks IL-4 responses, and CBP interaction domain maps to CBP aa 1850–2176.","method":"Co-immunoprecipitation, mammalian two-hybrid assay, E1A repression assay, reporter gene assays","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 1–2 — reciprocal Co-IP plus functional repression assays, multiple orthogonal methods","pmids":["10373589"],"is_preprint":false},{"year":1999,"finding":"IFN-α activates STAT6 in B cells in a cell-type-specific manner, leading to formation of novel STAT2:STAT6 heterodimeric complexes (including an ISGF3-like complex with STAT2, STAT6, and p48) that can target IFN-responsive elements.","method":"Tyrosine phosphorylation assays, EMSA, co-immunoprecipitation","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 — single lab, multiple biochemical methods demonstrating novel complex formation","pmids":["10490982"],"is_preprint":false},{"year":2000,"finding":"STAT6 mediates IL-4-induced repression of NF-κB- and STAT1-dependent transcription via distinct mechanisms: NF-κB repression requires STAT6 DNA binding (H415A mutation abolishes it) and involves CBP sequestration; STAT1 repression requires STAT6 transactivation domain but is DNA-binding-independent.","method":"Transient transfection in STAT6-deficient HEK293 cells, STAT6 point and deletion mutants, reporter assays","journal":"Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — reconstitution in STAT6-null cells with mutagenesis and multiple reporter systems","pmids":["10982806"],"is_preprint":false},{"year":2000,"finding":"IL-4 induces serine phosphorylation of STAT6 specifically within its transactivation domain (residues 719–789), independently of tyrosine phosphorylation at Y641 and independently of the IRS/PI3K, PKC, or MAPK pathways.","method":"Phosphoamino acid analysis, 2D phosphopeptide mapping, STAT6 deletion and point mutants in B cells","journal":"Molecular immunology","confidence":"High","confidence_rationale":"Tier 1 — biochemical mapping with multiple mutants and orthogonal phosphorylation analyses","pmids":["11164892"],"is_preprint":false},{"year":2000,"finding":"A gain-of-function STAT6 mutant (STAT6VT) with two SH2 domain amino acid changes undergoes constitutive tyrosine phosphorylation, DNA binding, and transcriptional activation independently of IL-4, via an IL-4-independent kinase.","method":"Site-directed mutagenesis, expression in JAK1/JAK3-deficient cells, DNA binding assay, reporter assay","journal":"Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — structure-function mutagenesis with mechanistic validation in kinase-deficient cells","pmids":["10747856"],"is_preprint":false},{"year":2001,"finding":"IL-4 and IL-13 inhibit NO production in macrophages via STAT6-dependent upregulation of arginase I, which depletes arginine (the iNOS substrate), rather than by directly inhibiting iNOS expression or activity.","method":"STAT6-knockout macrophages, arginase activity assay, arginine supplementation rescue, NO production assay, Toxoplasma killing assay","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — KO with multiple orthogonal assays and substrate rescue experiment","pmids":["11160269"],"is_preprint":false},{"year":2001,"finding":"IL-4-induced STAT6 blocks osteoclastogenesis by inhibiting NF-κB DNA binding; exogenous STAT6 protein directly inhibits NF-κB/DNA interaction, and this blockade is absent in STAT6-/- mice but rescued by exogenous STAT6 addition.","method":"STAT6 KO mice, EMSA with unlabeled STAT6 competitor, exogenous protein addition, osteoclastogenesis assay","journal":"Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 — KO rescue with exogenous protein plus in vitro DNA binding competition","pmids":["11390419"],"is_preprint":false},{"year":2001,"finding":"STAT6 is required for IL-4-induced cytoskeletal changes in B cells (spreading, polarization, microvilli formation) but is less critical for adhesion, indicating STAT6-dependent gene expression regulates cytoskeletal remodeling.","method":"STAT6-KO B cells, light and electron microscopy, adhesion assays","journal":"International immunology","confidence":"Medium","confidence_rationale":"Tier 2 — KO with defined morphological readouts, single study","pmids":["10882411"],"is_preprint":false},{"year":2002,"finding":"p100 protein (SN-like/tudor domain) is a coactivator for STAT6 that interacts with STAT6's transactivation domain, enhances STAT6-mediated transcription, and bridges STAT6 to RNA polymerase II.","method":"In vitro pulldown, Co-IP in vivo, reporter assays, RNA pol II co-immunoprecipitation","journal":"EMBO journal","confidence":"High","confidence_rationale":"Tier 2 — reciprocal Co-IP plus in vitro binding plus functional transcription assays","pmids":["12234934"],"is_preprint":false},{"year":2002,"finding":"Ym1 gene expression in macrophages is induced by IL-4 through STAT6-binding response elements in its promoter; STAT6 participates as an obligate component of protein complexes binding to these sites, confirmed by nuclear extracts from STAT6-deficient macrophages.","method":"Microarray, promoter reporter assays, EMSA with STAT6-null nuclear extracts, in vivo allergic peritonitis model","journal":"Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — functional promoter mapping with STAT6-null confirmation and in vivo validation","pmids":["12215441"],"is_preprint":false},{"year":2002,"finding":"Protein phosphatase 2A (PP2A) regulates STAT6 function: PP2A inhibition induces serine phosphorylation of STAT6 and severely inhibits its DNA binding without affecting JAK1 or tyrosine phosphorylation, placing PP2A downstream of JAKs.","method":"PP2A inhibitor treatment, phosphorylation assays, EMSA","journal":"Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 — pharmacological approach with clear mechanistic separation of tyrosine vs. serine phosphorylation effects","pmids":["12426308"],"is_preprint":false},{"year":2006,"finding":"RNA helicase A (RHA) is a component of the STAT6 transcription complex; it does not directly interact with STAT6 but is recruited via p100 to form a STAT6-p100-RHA ternary complex on IL-4-responsive promoters and enhances IL-4-induced transcription.","method":"In vitro and in vivo binding assays, chromatin immunoprecipitation, RNAi knockdown, reporter assay","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 2 — ChIP plus RNAi plus multiple binding assays demonstrating ternary complex","pmids":["16914450"],"is_preprint":false},{"year":2007,"finding":"CoaSt6 (collaborator of Stat6), a PARP-like protein, associates with STAT6 and possesses poly(ADP-ribosyl)ation activity; its catalytic activity is required for enhancement of STAT6-mediated transcription, and PARP inhibition blocks IL-4-dependent transcription.","method":"PARP enzymatic assay, catalytically inactive mutant, PARP chemical inhibitor, reporter assay, ADP-ribosylation of p100","journal":"Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — in vitro enzymatic assay plus mutagenesis plus pharmacological inhibition","pmids":["17478423"],"is_preprint":false},{"year":2007,"finding":"Kaempferol inhibits IL-4-induced STAT6 activation by specifically blocking the kinase activity of JAK3 (not JAK1), and has no effect in non-hematopoietic cell lines lacking JAK3, confirming JAK3 as the specific target.","method":"In vitro kinase assay, phosphorylation analysis, cell lines lacking JAK3","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 1 — in vitro kinase assay plus genetic cell-line confirmation","pmids":["17785825"],"is_preprint":false},{"year":2010,"finding":"STAT6 continuously shuttles into the nucleus independently of tyrosine phosphorylation via the coiled-coil domain and the classical importin-α/importin-β1 system; nuclear accumulation occurs after cytokine stimulation due to phosphorylation-dependent DNA binding rather than increased import.","method":"Live-cell imaging, FRAP, photobleaching, importin pathway inhibition, domain deletion analysis","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — live imaging with FRAP plus domain analysis, multiple orthogonal approaches","pmids":["20498360"],"is_preprint":false},{"year":2013,"finding":"STAT6 constitutively associates with mitochondria independently of tyrosine phosphorylation (SH2 domain and Y641); a truncated STAT6 lacking the SH2 domain still accumulates in MitoTracker-positive mitochondria.","method":"Live-cell imaging, immunofluorescence, electron microscopy, GFP fusion constructs, digitonin fractionation","journal":"PLoS ONE","confidence":"Medium","confidence_rationale":"Tier 2 — multiple imaging modalities and truncation constructs, single lab","pmids":["23383189"],"is_preprint":false},{"year":2014,"finding":"Grail (an E3 ubiquitin ligase) interacts with STAT6 and targets it for ubiquitination and proteasomal degradation, forming a negative feedback loop in Th2 cells that limits IL-4 receptor α and STAT6 levels.","method":"Co-IP, ubiquitination assay, Grail-KO mice, Th2 cell functional assays","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 — Co-IP plus ubiquitination assay plus KO phenotype, multiple orthogonal methods","pmids":["25145352"],"is_preprint":false},{"year":2016,"finding":"Crystal structure of phosphorylated STAT6 core fragment homodimer bound to N3 and N4 DNA reveals a dramatic conformational change upon DNA binding; H415 in the DNA-binding domain discriminates N4 from N3 sites, and H415N mutation decreases N4 affinity and increases N3 affinity both in vitro and in vivo.","method":"X-ray crystallography, molecular dynamics simulation, SAXS, mutagenesis, in vitro and in vivo DNA binding assays","journal":"PNAS","confidence":"High","confidence_rationale":"Tier 1 — crystal structure plus mutagenesis with functional validation, multiple methods","pmids":["27803324"],"is_preprint":false},{"year":2017,"finding":"NCOA1 (nuclear receptor coactivator 1) is required for STAT6 transcriptional activity; a stapled helical peptide disrupts the NCOA1/STAT6 protein-protein interaction and represses STAT6-mediated transcription, with first crystal structure of stapled peptide-NCOA1 complex solved.","method":"Stapled peptide design, crystal structure of peptide-NCOA1 complex, reporter assay, Co-IP disruption","journal":"Journal of the American Chemical Society","confidence":"High","confidence_rationale":"Tier 1 — crystal structure plus functional disruption assay","pmids":["29090910"],"is_preprint":false},{"year":2018,"finding":"IL-4-activated STAT6 directly represses inflammatory enhancers through an HDAC3-dependent mechanism on a subset of genes, reducing p300 and RNA Pol II binding, enhancer RNA expression, H3K27ac, and chromatin accessibility; STAT6-repressed enhancers overlap with the NF-κB p65 cistrome and exhibit decreased LPS responsiveness.","method":"ChIP-seq, ATAC-seq, RNA-seq in macrophages, HDAC3 inhibition, STAT6-KO mice, in vitro/in vivo IL-4 polarization","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 1–2 — genome-wide multimodal epigenomic approach with KO validation","pmids":["29343442"],"is_preprint":false},{"year":2019,"finding":"STAT6 is acetylated at Lys383 by CBP during macrophage activation; Trim24 (a CBP-associated E3 ligase) promotes STAT6 acetylation by ubiquitinating CBP at Lys119 to facilitate CBP recruitment to STAT6. Acetylation of STAT6 suppresses M2 polarization; Trim24 loss inhibits acetylation and promotes M2 polarization.","method":"Mass spectrometry identification of acetylation site, Co-IP, ubiquitination assay, Trim24 KO mice, human/mouse macrophage assays","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1–2 — MS-identified PTM, mechanistic Co-IP, KO validation in two species","pmids":["31554795"],"is_preprint":false},{"year":2019,"finding":"STAT6 activation in macrophages induces expression of the efferocytic ligand Gas6, which mediates clearance of apoptotic neutrophils; Gas6-depleted macrophages fail to clear apoptotic cells, and adoptive transfer of Gas6-expressing macrophages rescues efferocytosis in STAT6-KO mice.","method":"STAT6-KO mice, adoptive transfer, in vitro efferocytosis assay, bone marrow-derived macrophage priming","journal":"PNAS","confidence":"High","confidence_rationale":"Tier 2 — in vivo KO, adoptive transfer rescue, and in vitro mechanistic dissection","pmids":["31363052"],"is_preprint":false},{"year":2020,"finding":"TRAF6 stabilizes STAT6 protein by reducing K48-linked ubiquitination that would otherwise lead to proteasomal degradation; TRAF6 promotes K63-linked ubiquitination of STAT6 but this E3 ligase activity is dispensable for STAT6 stabilization, while TRAF6-STAT6 interaction requires the TRAF6 C domain.","method":"Co-IP, ubiquitination assay, TRAF6 KO/KD macrophages, STAT6 protein stability assay","journal":"Molecular immunology","confidence":"High","confidence_rationale":"Tier 2 — Co-IP plus ubiquitination assay with K48/K63 linkage discrimination and domain mapping","pmids":["33017719"],"is_preprint":false},{"year":2023,"finding":"TRAF3 promotes STAT6 ubiquitination at K450 (and K129) to enhance its transcriptional activity and M2 macrophage polarization; TRAF3 deficiency decreases STAT6 ubiquitination and abolishes IL-4-induced M2 polarization.","method":"Quantitative ubiquitomics (MS), site-directed mutagenesis (K450 mutation), ubiquitination assay, luciferase assay, TRAF3-KO mice melanoma model","journal":"Cell death and differentiation","confidence":"High","confidence_rationale":"Tier 1–2 — MS-based ubiquitomics plus mutagenesis plus functional reporter assays plus in vivo KO","pmids":["37474750"],"is_preprint":false},{"year":2022,"finding":"STAT6 inhibits ferroptosis in lung epithelial cells by competitively binding to CBP, thereby inhibiting CBP-mediated acetylation of p53 and transcriptionally restoring SLC7A11 (a ferroptosis suppressor) expression.","method":"STAT6 conditional KO mice, STAT6 overexpression, Co-IP (STAT6-CBP), p53 acetylation assay, SLC7A11 expression analysis","journal":"Cell death and disease","confidence":"High","confidence_rationale":"Tier 2 — KO plus OE plus Co-IP plus acetylation assay, multiple orthogonal methods","pmids":["35668064"],"is_preprint":false},{"year":2001,"finding":"Stat6 is required for Th2-mediated intestinal goblet cell hyperplasia during nematode infection; STAT6-deficient mice fail to generate infection-induced goblet cell hyperplasia, correlating with impaired IL-4/IL-13 production and reduced parasite expulsion.","method":"STAT6-KO mice, parasite infection model, goblet cell quantification","journal":"Parasite immunology","confidence":"Medium","confidence_rationale":"Tier 2 — clean KO with defined cellular phenotype, single lab","pmids":["11136476"],"is_preprint":false},{"year":2001,"finding":"A peptide derived from the STAT6-binding region of IL-4Rα, when delivered intracellularly, completely inhibits IL-4-dependent tyrosine phosphorylation of STAT6 and STAT6-dependent transcription, without affecting STAT5 phosphorylation.","method":"Cell-permeable peptide delivery, phosphorylation assay, reporter gene assay","journal":"European journal of biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 — mechanistic peptide inhibition with specificity controls","pmids":["11532018"],"is_preprint":false},{"year":2016,"finding":"STAT3 and STAT6 synergize to upregulate cathepsin secretion by macrophages via engagement of IRE1α (UPR sensor); pharmacological inhibition of IRE1α blocks cathepsin secretion and macrophage-mediated cancer cell invasion.","method":"Whole-genome expression analysis, IRE1α pharmacological inhibition, STAT3/STAT6 genetic deletion, invasion assay","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 — genome-wide analysis plus pharmacological and genetic intervention, multiple readouts","pmids":["27626662"],"is_preprint":false},{"year":2014,"finding":"B-cell-intrinsic STAT6 signaling is required for germinal center formation; STAT6 deficiency in B cells results in failure to downregulate the chemotactic receptor Gpr183/Ebi2, which is essential for proper GC B-cell positioning and differentiation.","method":"Conditional B-cell STAT6 deficiency (BM chimeras), helminth infection model, flow cytometry, GC B-cell analysis","journal":"European journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — cell-type-specific KO with mechanistic identification of Gpr183 as downstream target","pmids":["24777733"],"is_preprint":false},{"year":2007,"finding":"STAT6 mediates IL-4/IL-13-induced downregulation of skin barrier proteins loricrin and involucrin in keratinocytes; STAT6 transgenic mice are deficient in loricrin and involucrin expression.","method":"Primary keratinocyte cultures, siRNA/transgenic mouse model, gene/protein expression analysis","journal":"Clinical immunology","confidence":"Medium","confidence_rationale":"Tier 2 — transgenic model plus in vitro cytokine treatment, mechanistic pathway identified","pmids":["18166499"],"is_preprint":false},{"year":2023,"finding":"Germline gain-of-function STAT6 mutation (E372K in DNA-binding domain) augments both basal and cytokine-induced STAT6 phosphorylation, causes preferential nuclear localization, and drives severe allergic disease; JAK1/2 inhibitor ruxolitinib reverses STAT6 hyperresponsiveness.","method":"Whole-exome sequencing, EMSA, luciferase assay, Western blot, immunofluorescence, JAK inhibitor treatment, gastric organoids","journal":"Journal of allergy and clinical immunology","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal functional assays in patient and engineered cells","pmids":["36758835"],"is_preprint":false},{"year":2022,"finding":"Germline STAT6 gain-of-function variant (E377K in DNA-binding domain) results in spontaneous STAT6 transcriptional activity, strong preference for nuclear localization, increased DNA binding affinity, and constitutive activation of downstream signaling in gastric organoids.","method":"Exome sequencing, EMSA, luciferase assay, immunofluorescence, gastric organoids, Western blot","journal":"Journal of allergy and clinical immunology","confidence":"High","confidence_rationale":"Tier 2 — multiple functional assays in patient cells plus organoid model","pmids":["36216080"],"is_preprint":false},{"year":2015,"finding":"IL-4-induced STAT6 and KLF4 implement M2 macrophage polarization via induction of MCPIP, which inhibits NF-κB activation (deubiquitinase activity) and drives M2 polarization through its RNase activity causing sequential ROS, ER stress, and autophagy induction.","method":"Murine macrophages, myeloid-specific MCPIP overexpression/KO mice, M1/M2 polarization assays","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — in vivo KO and OE models with defined molecular mechanism","pmids":["25934862"],"is_preprint":false},{"year":2000,"finding":"STAT6 NF-κB inhibition involves inhibition of IκBα phosphorylation and degradation (blocking NF-κB nuclear import), while glucocorticoid receptor acts by increasing p65 nuclear export rate; STAT6 and GR thus inhibit NF-κB by distinct mechanisms.","method":"Fluorescent fusion protein live imaging, NF-κB reporter assay, IκBα phosphorylation assay","journal":"Journal of cell science","confidence":"High","confidence_rationale":"Tier 2 — live imaging with functional reporter assays, mechanistic dissection of two pathways","pmids":["12734399"],"is_preprint":false},{"year":2017,"finding":"Lyn kinase negatively regulates IL-4/IL-13-induced STAT6 activation and MUC5AC expression; Lyn overexpression decreases STAT6 phosphorylation and chromatin binding to the MUC5AC promoter, while Lyn knockdown increases STAT6 and MUC5AC levels.","method":"Chromatin immunoprecipitation, overexpression/knockdown in cells and OVA-challenged mice, STAT6 phosphorylation assay","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP plus in vivo mouse model, single lab","pmids":["28205598"],"is_preprint":false},{"year":2020,"finding":"IL-4 stimulates lipogenesis in meibomian gland epithelial cells through a STAT6/PPARγ signaling pathway; STAT6 phosphorylation inhibition suppresses IL-4-mediated lipid synthesis and PPARγ/SREBP-1 expression.","method":"IL-4 treatment with STAT6 inhibitor, Western blot, lipid staining, HGMEC culture","journal":"Ocular surface","confidence":"Medium","confidence_rationale":"Tier 2 — pharmacological inhibition with defined signaling pathway and lipid readout","pmids":["32360783"],"is_preprint":false},{"year":2022,"finding":"Gain-of-function STAT6 mutations in follicular lymphoma (DNA-binding domain) enhance IL-4-induced transcription at the PARP14 promoter; STAT6MUT binds PARP14 promoter (not STAT6WT by ChIP), creating a self-reinforcing circuit; PARP14 knockdown or PARP inhibition abrogates the STAT6MUT gain-of-function phenotype.","method":"qChIP, reporter assay, RNA-seq, CRISPR KD, PARP inhibitor treatment, pre-B CFU assay","journal":"Leukemia","confidence":"High","confidence_rationale":"Tier 2 — ChIP plus reporter plus genetic rescue with multiple orthogonal approaches","pmids":["35851155"],"is_preprint":false}],"current_model":"STAT6 is a latent transcription factor activated primarily by IL-4 and IL-13 via JAK-mediated tyrosine phosphorylation (at Y641) of its SH2 domain, which drives homodimerization, nuclear import via importin-α/β, and DNA binding at N4 elements through a unique H415 residue; once nuclear, STAT6 recruits coactivators p300/CBP, p100, RHA, NCOA1, and CoaSt6 (a PARP) to activate target genes (arginase I, Gas6, Ym1, MUC5AC, etc.), and simultaneously represses inflammatory enhancers via HDAC3 and NF-κB sequestration; STAT6 activity is fine-tuned by acetylation at K383 by CBP (suppressive), ubiquitination at K450 by TRAF3 (activating), proteasomal degradation via Grail/TRAF6-mediated ubiquitination, and dephosphorylation by PP2A, while gain-of-function mutations in its DNA-binding domain cause constitutive signaling and severe allergic disease."},"narrative":{"teleology":[{"year":1996,"claim":"Establishing STAT6 as the non-redundant mediator of IL-4 and IL-13 biological responses resolved which STAT family member transduces these cytokine signals in vivo.","evidence":"Stat6-knockout mice showing abolished IL-4-induced B-cell proliferation, CD23/MHC II upregulation, and IL-13-induced macrophage responses","pmids":["8602263","8871614"],"confidence":"High","gaps":["Relative contribution of STAT6 to IL-4 versus IL-13 signaling in individual cell types not fully dissected","Downstream transcriptional targets not yet identified at this stage"]},{"year":1997,"claim":"Mapping the STAT6 domain architecture — a C-terminal proline-rich transactivation domain and an SH2 domain with separable receptor-binding and dimerization functions — defined the structural basis for signal transduction from receptor to DNA.","evidence":"Gal4 fusion/deletion mutant reporter assays and systematic alanine-scanning mutagenesis of the SH2 domain","pmids":["9233621","9651359"],"confidence":"High","gaps":["Three-dimensional structure not yet available","Serine phosphorylation contributions to transactivation unknown"]},{"year":1999,"claim":"Identification of p300/CBP as a STAT6 coactivator and discovery that IFN-α can activate STAT6 in B cells via STAT2:STAT6 heterodimers expanded the mechanistic picture beyond the IL-4/IL-13 paradigm.","evidence":"Co-IP and mammalian two-hybrid mapping CBP interaction to STAT6 TAD; EMSA and Co-IP showing STAT2:STAT6 heterodimers in IFN-α-treated B cells","pmids":["10373589","10490982"],"confidence":"High","gaps":["Structural basis of CBP-STAT6 interaction not resolved","Physiological relevance of STAT2:STAT6 in IFN signaling not confirmed in vivo"]},{"year":2000,"claim":"Dissection of how STAT6 represses NF-κB (via DNA-binding-dependent CBP competition and IκBα stabilization) and STAT1 (via TAD-dependent, DNA-binding-independent mechanisms) revealed STAT6 as an active transcriptional repressor, not merely an activator.","evidence":"STAT6 point mutants (H415A) in STAT6-null HEK293 reconstitution, live-cell NF-κB reporter imaging, IκBα phosphorylation assays","pmids":["10982806","12734399"],"confidence":"High","gaps":["Genome-wide repression targets unknown","Whether repression requires new protein synthesis or is direct was unresolved"]},{"year":2000,"claim":"Identification of serine phosphorylation within the STAT6 TAD (residues 719–789) occurring independently of Y641 and the IRS/PI3K/MAPK pathways, plus the observation that PP2A regulates DNA binding via serine dephosphorylation, revealed a second layer of post-translational regulation.","evidence":"2D phosphopeptide mapping with STAT6 deletion mutants; PP2A inhibitor treatment separating serine from tyrosine phosphorylation effects","pmids":["11164892","12426308"],"confidence":"High","gaps":["Identity of the serine kinase unknown","Specific serine residues not pinpointed","Physiological role of serine phosphorylation in vivo not tested"]},{"year":2001,"claim":"Downstream of STAT6, identification of arginase I as the effector suppressing NO production in macrophages, and demonstration of STAT6 requirement for goblet cell hyperplasia during nematode infection, linked STAT6 to defined anti-inflammatory and mucosal defense programs.","evidence":"STAT6-KO macrophages with arginine supplementation rescue; STAT6-KO mice in nematode infection model","pmids":["11160269","11136476"],"confidence":"High","gaps":["Full repertoire of STAT6-dependent target genes not catalogued","Direct versus indirect transcriptional effects not distinguished genome-wide"]},{"year":2002,"claim":"Discovery of p100 as a STAT6 coactivator bridging STAT6 to RNA Pol II, and identification of STAT6-dependent Ym1 promoter elements, began to define the transcription complex architecture at target genes.","evidence":"Reciprocal Co-IP and in vitro pulldown for p100-STAT6 and p100-Pol II; EMSA with STAT6-null nuclear extracts on Ym1 promoter","pmids":["12234934","12215441"],"confidence":"High","gaps":["Whether p100 is constitutive or stimulus-recruited was unclear","Genome-wide occupancy of the STAT6-p100 complex not mapped"]},{"year":2006,"claim":"Assembly of a ternary STAT6–p100–RNA helicase A complex on IL-4-responsive promoters, and discovery that the PARP-family protein CoaSt6 enhances STAT6 transcription through poly(ADP-ribosyl)ation activity, revealed enzymatic cofactors within the STAT6 transactivation machinery.","evidence":"ChIP plus RNAi for RHA; in vitro PARP assay with catalytically inactive CoaSt6 mutant and pharmacological PARP inhibition","pmids":["16914450","17478423"],"confidence":"High","gaps":["ADP-ribosylation substrates beyond p100 not identified","Whether RHA helicase activity is required was not tested"]},{"year":2010,"claim":"Live-cell imaging demonstrated that STAT6 constitutively shuttles into the nucleus via the coiled-coil domain and importin-α/β, with cytokine-induced nuclear accumulation resulting from phosphorylation-dependent DNA retention rather than increased import, resolving the mechanism of signal-dependent nuclear concentration.","evidence":"FRAP and photobleaching with importin pathway inhibition and domain deletions","pmids":["20498360"],"confidence":"High","gaps":["Nuclear export pathway not characterized","Whether other nuclear factors contribute to retention beyond DNA binding was unclear"]},{"year":2014,"claim":"Identification of Grail as an E3 ligase mediating STAT6 proteasomal degradation, and demonstration of B-cell-intrinsic STAT6 requirement for germinal center formation via Gpr183/Ebi2 regulation, expanded understanding of both STAT6 turnover and its cell-type-specific functions.","evidence":"Co-IP and ubiquitination assay with Grail-KO Th2 cells; conditional B-cell STAT6 KO in helminth infection model with Gpr183 expression analysis","pmids":["25145352","24777733"],"confidence":"High","gaps":["Ubiquitin chain linkage type for Grail-mediated degradation not determined","Whether Gpr183 is a direct STAT6 transcriptional target not shown"]},{"year":2016,"claim":"The crystal structure of phosphorylated STAT6 homodimer bound to DNA revealed the structural basis for N4-site selectivity through H415 and a dramatic conformational rearrangement upon DNA binding, providing the first atomic-resolution view of STAT6 target recognition.","evidence":"X-ray crystallography, SAXS, molecular dynamics, and H415N mutagenesis with in vitro/in vivo DNA binding","pmids":["27803324"],"confidence":"High","gaps":["Structure of full-length STAT6 (including TAD) not solved","How coactivators dock onto the DNA-bound dimer not structurally defined"]},{"year":2017,"claim":"Structural and functional characterization of the NCOA1–STAT6 interaction, and identification of a stapled peptide that disrupts it and blocks STAT6-dependent transcription, validated NCOA1 as an essential STAT6 coactivator and demonstrated therapeutic targetability.","evidence":"Crystal structure of stapled peptide–NCOA1 complex, reporter assay, Co-IP disruption","pmids":["29090910"],"confidence":"High","gaps":["Whether NCOA1 is required at all STAT6 target genes or a subset was not determined","In vivo efficacy of the stapled peptide not tested"]},{"year":2018,"claim":"Genome-wide epigenomic profiling revealed that STAT6 actively represses inflammatory enhancers through HDAC3-dependent deacetylation — reducing p300, Pol II, eRNA, H3K27ac, and chromatin accessibility at NF-κB-co-occupied sites — establishing enhancer-level repression as a primary anti-inflammatory mechanism.","evidence":"ChIP-seq, ATAC-seq, RNA-seq in WT and STAT6-KO macrophages with HDAC3 inhibition","pmids":["29343442"],"confidence":"High","gaps":["How STAT6 recruits HDAC3 (direct interaction or adaptor-mediated) not established","Whether repression is reversible upon STAT6 removal not kinetically resolved"]},{"year":2019,"claim":"Discovery that CBP acetylates STAT6 at K383 to suppress M2 polarization (promoted by Trim24-mediated CBP ubiquitination), and that STAT6 induces Gas6 for efferocytosis, revealed acetylation as a suppressive modification and identified a physiological output linking STAT6 to apoptotic cell clearance.","evidence":"MS identification of K383 acetylation, Trim24-KO macrophages; STAT6-KO adoptive transfer rescuing efferocytosis with Gas6-expressing macrophages","pmids":["31554795","31363052"],"confidence":"High","gaps":["Deacetylase responsible for removing K383 acetylation not identified","Whether Gas6 induction is a direct or indirect STAT6 target not determined"]},{"year":2020,"claim":"TRAF6 was shown to stabilize STAT6 by blocking K48-linked ubiquitination, while STAT6 was also found to inhibit ferroptosis by competing with p53 for CBP binding to restore SLC7A11, revealing non-canonical STAT6 functions in protein stability and cell death pathways.","evidence":"TRAF6-KD macrophages with K48/K63 ubiquitin linkage discrimination; STAT6 conditional KO mice with p53 acetylation and SLC7A11 expression assays","pmids":["33017719","35668064"],"confidence":"High","gaps":["Whether TRAF6-STAT6 stabilization is cytokine-dependent or constitutive not fully resolved","Generality of STAT6 anti-ferroptotic function beyond lung epithelium unknown"]},{"year":2022,"claim":"Identification of germline gain-of-function STAT6 mutations (E377K, E372K) in the DNA-binding domain causing constitutive nuclear localization, enhanced DNA binding, and severe early-onset allergic disease — reversible by JAK inhibition — established STAT6 as a Mendelian disease gene and validated the clinical relevance of its structural biology.","evidence":"Whole-exome sequencing in patients, EMSA, luciferase assays, immunofluorescence, gastric organoids, ruxolitinib rescue","pmids":["36216080","36758835"],"confidence":"High","gaps":["Full phenotypic spectrum of STAT6 gain-of-function in humans not delineated","Structural mechanism by which DNA-binding domain mutations cause constitutive activation not crystallographically resolved"]},{"year":2023,"claim":"TRAF3 was identified as an E3 ligase ubiquitinating STAT6 at K450 to enhance its transcriptional activity and M2 polarization, while somatic STAT6 gain-of-function mutations in follicular lymphoma were shown to create a self-reinforcing STAT6–PARP14 circuit, linking STAT6 regulation to both innate immunity and lymphomagenesis.","evidence":"Quantitative ubiquitomics with K450 mutagenesis and TRAF3-KO mice; ChIP showing STAT6MUT-specific PARP14 promoter binding with PARP inhibitor rescue in pre-B CFU assay","pmids":["37474750","35851155"],"confidence":"High","gaps":["Ubiquitin chain type at K450 not fully characterized","Whether PARP14 circuit operates in human follicular lymphoma patients in vivo not confirmed"]},{"year":null,"claim":"Key unresolved questions include the identity of the kinase responsible for STAT6 serine phosphorylation in the TAD, the structural basis of full-length STAT6 interaction with its coactivator complex, the mechanism of HDAC3 recruitment to STAT6-repressed enhancers, and the physiological significance of constitutive STAT6 mitochondrial association.","evidence":"","pmids":[],"confidence":"Low","gaps":["Serine kinase for TAD phosphorylation unidentified","Full-length STAT6 structure including TAD and coactivator contacts not solved","HDAC3 recruitment mechanism to STAT6 at enhancers not defined","Functional role of STAT6 at mitochondria uncharacterized"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[3,7,9,22,35,36]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[2,5,7,13,14,24,29]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[19,22,35,36]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[19]},{"term_id":"GO:0005739","term_label":"mitochondrion","supporting_discovery_ids":[20]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,1,3,8,18,35]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[0,1,10,11,24,26,30,33,37]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[2,5,7,13,14,16,17,22,23,24]},{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[24,25]}],"complexes":["STAT6-p100-RHA ternary complex","STAT2:STAT6 heterodimer"],"partners":["CBP","NCOA1","TSN","DHX9","TRAF3","TRAF6","RNF128","TIPARP"],"other_free_text":[]},"mechanistic_narrative":"STAT6 is a latent transcription factor that serves as the central mediator of IL-4 and IL-13 signaling, governing Th2 immunity, alternative macrophage activation, and allergic inflammation. Upon cytokine stimulation, JAK3-mediated tyrosine phosphorylation at Y641 promotes SH2-domain-dependent homodimerization and DNA binding to N4-spaced GAS elements — a specificity conferred by H415 in the DNA-binding domain — while STAT6 continuously shuttles into the nucleus via importin-α/β through its coiled-coil domain independently of phosphorylation, with nuclear accumulation driven by DNA retention [PMID:8602263, PMID:9651359, PMID:27803324, PMID:20498360]. Nuclear STAT6 recruits a multicomponent coactivator assembly (p300/CBP, p100, RNA helicase A, NCOA1, and the PARP-family protein CoaSt6) to activate target genes including arginase I, Ym1, Gas6, and MUC5AC, while simultaneously repressing inflammatory enhancers through HDAC3-dependent chromatin deacetylation and inhibition of NF-κB DNA binding via IκBα stabilization and CBP sequestration [PMID:10373589, PMID:12234934, PMID:16914450, PMID:29090910, PMID:29343442, PMID:10982806]. STAT6 protein levels and activity are tuned by suppressive acetylation at K383 by CBP (promoted by Trim24-mediated CBP ubiquitination), activating ubiquitination at K450 by TRAF3, stabilization by TRAF6 through blockade of K48-linked ubiquitination, and proteasomal degradation directed by the E3 ligase Grail [PMID:31554795, PMID:37474750, PMID:33017719, PMID:25145352]. Germline gain-of-function mutations in the STAT6 DNA-binding domain (E372K, E377K) cause constitutive nuclear localization and transcriptional activation, resulting in severe early-onset allergic disease [PMID:36758835, PMID:36216080]."},"prefetch_data":{"uniprot":{"accession":"P42226","full_name":"Signal transducer and activator of transcription 6","aliases":["IL-4 Stat"],"length_aa":847,"mass_kda":94.1,"function":"Carries out a dual function: signal transduction and activation of transcription. Involved in IL4/interleukin-4- and IL3/interleukin-3-mediated signaling","subcellular_location":"Cytoplasm; Nucleus","url":"https://www.uniprot.org/uniprotkb/P42226/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/STAT6","classification":"Not Classified","n_dependent_lines":7,"n_total_lines":1208,"dependency_fraction":0.005794701986754967},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/STAT6","total_profiled":1310},"omim":[{"mim_id":"620532","title":"HYPER-IgE SYNDROME 6, AUTOSOMAL DOMINANT, WITH RECURRENT INFECTIONS; HIES6","url":"https://www.omim.org/entry/620532"},{"mim_id":"620480","title":"TRIPARTITE MOTIF FAMILY-LIKE PROTEIN 2; TRIML2","url":"https://www.omim.org/entry/620480"},{"mim_id":"620432","title":"OSTEOCLAST STIMULATORY TRANSMEMBRANE PROTEIN; OCSTAMP","url":"https://www.omim.org/entry/620432"},{"mim_id":"612374","title":"STIMULATOR OF INTERFERON RESPONSE cGAMP INTERACTOR 1; STING1","url":"https://www.omim.org/entry/612374"},{"mim_id":"610028","title":"POLY(ADP-RIBOSE) POLYMERASE FAMILY, MEMBER 14; PARP14","url":"https://www.omim.org/entry/610028"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"},{"location":"Cytosol","reliability":"Supported"},{"location":"Connecting piece","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/STAT6"},"hgnc":{"alias_symbol":["D12S1644","IL-4-STAT"],"prev_symbol":[]},"alphafold":{"accession":"P42226","domains":[{"cath_id":"1.10.532.10","chopping":"2-118","consensus_level":"medium","plddt":88.0283,"start":2,"end":118},{"cath_id":"2.60.40.630","chopping":"279-326_336-417","consensus_level":"high","plddt":89.4992,"start":279,"end":417},{"cath_id":"3.30.505.10","chopping":"446-629","consensus_level":"high","plddt":95.2121,"start":446,"end":629},{"cath_id":"1.20.58","chopping":"119-158_176-271","consensus_level":"medium","plddt":91.3504,"start":119,"end":271}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P42226","model_url":"https://alphafold.ebi.ac.uk/files/AF-P42226-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P42226-F1-predicted_aligned_error_v6.png","plddt_mean":76.5},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=STAT6","jax_strain_url":"https://www.jax.org/strain/search?query=STAT6"},"sequence":{"accession":"P42226","fasta_url":"https://rest.uniprot.org/uniprotkb/P42226.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P42226/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P42226"}},"corpus_meta":[{"pmid":"8602263","id":"PMC_8602263","title":"Essential role of Stat6 in IL-4 signalling.","date":"1996","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/8602263","citation_count":1237,"is_preprint":false},{"pmid":"24030747","id":"PMC_24030747","title":"Nuclear expression of STAT6 distinguishes solitary fibrous tumor from histologic mimics.","date":"2013","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/24030747","citation_count":568,"is_preprint":false},{"pmid":"18166499","id":"PMC_18166499","title":"Loricrin and involucrin expression is down-regulated by Th2 cytokines through STAT-6.","date":"2007","source":"Clinical immunology (Orlando, Fla.)","url":"https://pubmed.ncbi.nlm.nih.gov/18166499","citation_count":415,"is_preprint":false},{"pmid":"31554795","id":"PMC_31554795","title":"Modulation of M2 macrophage polarization by the crosstalk between Stat6 and Trim24.","date":"2019","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/31554795","citation_count":293,"is_preprint":false},{"pmid":"16540365","id":"PMC_16540365","title":"Signaling mechanisms, interaction partners, and target genes of STAT6.","date":"2006","source":"Cytokine & growth factor reviews","url":"https://pubmed.ncbi.nlm.nih.gov/16540365","citation_count":248,"is_preprint":false},{"pmid":"31619589","id":"PMC_31619589","title":"STAT6/Arg1 promotes microglia/macrophage efferocytosis and inflammation resolution in stroke mice.","date":"2019","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/31619589","citation_count":244,"is_preprint":false},{"pmid":"11160269","id":"PMC_11160269","title":"Cutting edge: Stat6-dependent substrate depletion regulates nitric oxide production.","date":"2001","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/11160269","citation_count":238,"is_preprint":false},{"pmid":"10851056","id":"PMC_10851056","title":"The biology of Stat4 and Stat6.","date":"2000","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/10851056","citation_count":231,"is_preprint":false},{"pmid":"29343442","id":"PMC_29343442","title":"The Transcription Factor STAT6 Mediates Direct Repression of Inflammatory Enhancers and Limits Activation of Alternatively Polarized Macrophages.","date":"2018","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/29343442","citation_count":203,"is_preprint":false},{"pmid":"8871614","id":"PMC_8871614","title":"Impaired IL-13-mediated functions of macrophages in STAT6-deficient mice.","date":"1996","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/8871614","citation_count":183,"is_preprint":false},{"pmid":"12215441","id":"PMC_12215441","title":"TH2 cytokines and allergic challenge induce Ym1 expression in macrophages by a STAT6-dependent mechanism.","date":"2002","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12215441","citation_count":179,"is_preprint":false},{"pmid":"35668064","id":"PMC_35668064","title":"STAT6 inhibits ferroptosis and alleviates acute lung injury via regulating P53/SLC7A11 pathway.","date":"2022","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/35668064","citation_count":158,"is_preprint":false},{"pmid":"11390419","id":"PMC_11390419","title":"IL-4 abrogates osteoclastogenesis through STAT6-dependent inhibition of NF-kappaB.","date":"2001","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/11390419","citation_count":157,"is_preprint":false},{"pmid":"27626662","id":"PMC_27626662","title":"STAT3 and STAT6 Signaling Pathways Synergize to Promote Cathepsin Secretion from Macrophages via IRE1α Activation.","date":"2016","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/27626662","citation_count":156,"is_preprint":false},{"pmid":"25873501","id":"PMC_25873501","title":"Extensive survey of STAT6 expression in a large series of mesenchymal tumors.","date":"2015","source":"American journal of clinical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/25873501","citation_count":156,"is_preprint":false},{"pmid":"25934862","id":"PMC_25934862","title":"Transcription factors STAT6 and KLF4 implement macrophage polarization via the dual catalytic powers of MCPIP.","date":"2015","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/25934862","citation_count":154,"is_preprint":false},{"pmid":"12234934","id":"PMC_12234934","title":"Identification of p100 as a coactivator for STAT6 that bridges STAT6 with RNA polymerase II.","date":"2002","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/12234934","citation_count":146,"is_preprint":false},{"pmid":"31363052","id":"PMC_31363052","title":"STAT6 induces expression of Gas6 in macrophages to clear apoptotic neutrophils and resolve inflammation.","date":"2019","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/31363052","citation_count":113,"is_preprint":false},{"pmid":"16322752","id":"PMC_16322752","title":"PKCzeta at the crossroad of NF-kappaB and Jak1/Stat6 signaling pathways.","date":"2006","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/16322752","citation_count":108,"is_preprint":false},{"pmid":"10373589","id":"PMC_10373589","title":"p300/CBP is required for transcriptional induction by interleukin-4 and interacts with Stat6.","date":"1999","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/10373589","citation_count":106,"is_preprint":false},{"pmid":"9181473","id":"PMC_9181473","title":"STAT6: its role in interleukin 4-mediated biological functions.","date":"1997","source":"Journal of molecular medicine (Berlin, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/9181473","citation_count":97,"is_preprint":false},{"pmid":"15585884","id":"PMC_15585884","title":"Pulmonary chemokine expression is coordinately regulated by STAT1, STAT6, and IFN-gamma.","date":"2004","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/15585884","citation_count":92,"is_preprint":false},{"pmid":"11136476","id":"PMC_11136476","title":"Stat6 dependent goblet cell hyperplasia during intestinal nematode infection.","date":"2001","source":"Parasite immunology","url":"https://pubmed.ncbi.nlm.nih.gov/11136476","citation_count":91,"is_preprint":false},{"pmid":"10982806","id":"PMC_10982806","title":"Interleukin-4/STAT6 represses STAT1 and NF-kappa B-dependent transcription through distinct mechanisms.","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10982806","citation_count":90,"is_preprint":false},{"pmid":"14500660","id":"PMC_14500660","title":"Identification of novel IL-4/Stat6-regulated genes in T lymphocytes.","date":"2003","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/14500660","citation_count":86,"is_preprint":false},{"pmid":"33991851","id":"PMC_33991851","title":"STAT6: A review of a signaling pathway implicated in various diseases with a special emphasis in its usefulness in pathology.","date":"2021","source":"Pathology, research and practice","url":"https://pubmed.ncbi.nlm.nih.gov/33991851","citation_count":80,"is_preprint":false},{"pmid":"17478423","id":"PMC_17478423","title":"Collaborator of Stat6 (CoaSt6)-associated poly(ADP-ribose) polymerase activity modulates Stat6-dependent gene transcription.","date":"2007","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17478423","citation_count":77,"is_preprint":false},{"pmid":"27113293","id":"PMC_27113293","title":"IL-13 mediates collagen deposition via STAT6 and microRNA-135b: a role for epigenetics.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/27113293","citation_count":72,"is_preprint":false},{"pmid":"10490982","id":"PMC_10490982","title":"IFN-alpha activates Stat6 and leads to the formation of Stat2:Stat6 complexes in B cells.","date":"1999","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/10490982","citation_count":72,"is_preprint":false},{"pmid":"23303670","id":"PMC_23303670","title":"STAT6 deficiency ameliorates severity of oxazolone colitis by decreasing expression of claudin-2 and Th2-inducing cytokines.","date":"2013","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/23303670","citation_count":72,"is_preprint":false},{"pmid":"26208975","id":"PMC_26208975","title":"Targeting IL13Ralpha2 activates STAT6-TP63 pathway to suppress breast cancer lung metastasis.","date":"2015","source":"Breast cancer research : BCR","url":"https://pubmed.ncbi.nlm.nih.gov/26208975","citation_count":71,"is_preprint":false},{"pmid":"25287927","id":"PMC_25287927","title":"Mycoplasma pneumoniae modulates STAT3-STAT6/EGFR-FOXA2 signaling to induce overexpression of airway mucins.","date":"2014","source":"Infection and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/25287927","citation_count":70,"is_preprint":false},{"pmid":"37474750","id":"PMC_37474750","title":"TRAF3/STAT6 axis regulates macrophage polarization and tumor progression.","date":"2023","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/37474750","citation_count":67,"is_preprint":false},{"pmid":"28235236","id":"PMC_28235236","title":"PVT1-derived miR-1207-5p promotes breast cancer cell growth by targeting STAT6.","date":"2017","source":"Cancer science","url":"https://pubmed.ncbi.nlm.nih.gov/28235236","citation_count":66,"is_preprint":false},{"pmid":"12734399","id":"PMC_12734399","title":"NF-kappaB signalling is inhibited by glucocorticoid receptor and STAT6 via distinct mechanisms.","date":"2003","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/12734399","citation_count":66,"is_preprint":false},{"pmid":"12082548","id":"PMC_12082548","title":"STAT6 mediates interleukin-4 growth inhibition in human breast cancer cells.","date":"2002","source":"Neoplasia (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/12082548","citation_count":62,"is_preprint":false},{"pmid":"19494273","id":"PMC_19494273","title":"Small interfering RNA against transcription factor STAT6 inhibits allergic airway inflammation and hyperreactivity in mice.","date":"2009","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/19494273","citation_count":62,"is_preprint":false},{"pmid":"24777733","id":"PMC_24777733","title":"B-cell-intrinsic STAT6 signaling controls germinal center formation.","date":"2014","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/24777733","citation_count":61,"is_preprint":false},{"pmid":"21321603","id":"PMC_21321603","title":"Cisplatin ototoxicity involves cytokines and STAT6 signaling network.","date":"2011","source":"Cell research","url":"https://pubmed.ncbi.nlm.nih.gov/21321603","citation_count":61,"is_preprint":false},{"pmid":"17785825","id":"PMC_17785825","title":"Kaempferol inhibits IL-4-induced STAT6 activation by specifically targeting JAK3.","date":"2007","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/17785825","citation_count":60,"is_preprint":false},{"pmid":"16213149","id":"PMC_16213149","title":"The role of constitutively active Stat6 in leukemia and lymphoma.","date":"2005","source":"Critical reviews in oncology/hematology","url":"https://pubmed.ncbi.nlm.nih.gov/16213149","citation_count":58,"is_preprint":false},{"pmid":"10514388","id":"PMC_10514388","title":"IL-13 activates STAT6 and inhibits liver injury induced by ischemia/reperfusion.","date":"1999","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/10514388","citation_count":58,"is_preprint":false},{"pmid":"26883114","id":"PMC_26883114","title":"NAB2-STAT6 Gene Fusion in Meningeal Hemangiopericytoma and Solitary Fibrous Tumor.","date":"2016","source":"Journal of neuropathology and experimental neurology","url":"https://pubmed.ncbi.nlm.nih.gov/26883114","citation_count":57,"is_preprint":false},{"pmid":"27803324","id":"PMC_27803324","title":"Structural basis for DNA recognition by STAT6.","date":"2016","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/27803324","citation_count":57,"is_preprint":false},{"pmid":"9834104","id":"PMC_9834104","title":"Mice with STAT6-targeted gene disruption develop a Th1 response and control cutaneous leishmaniasis.","date":"1998","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/9834104","citation_count":56,"is_preprint":false},{"pmid":"10747856","id":"PMC_10747856","title":"A gain-of-function mutation in STAT6.","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10747856","citation_count":53,"is_preprint":false},{"pmid":"36758835","id":"PMC_36758835","title":"Severe allergic dysregulation due to a gain of function mutation in the transcription factor STAT6.","date":"2023","source":"The Journal of allergy and clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/36758835","citation_count":51,"is_preprint":false},{"pmid":"9233621","id":"PMC_9233621","title":"Identification of a STAT6 domain required for IL-4-induced activation of transcription.","date":"1997","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/9233621","citation_count":49,"is_preprint":false},{"pmid":"9651359","id":"PMC_9651359","title":"Mutational analysis of the STAT6 SH2 domain.","date":"1998","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9651359","citation_count":49,"is_preprint":false},{"pmid":"33745702","id":"PMC_33745702","title":"Clinical and molecular implications of NAB2-STAT6 fusion variants in solitary fibrous tumour.","date":"2021","source":"Pathology","url":"https://pubmed.ncbi.nlm.nih.gov/33745702","citation_count":48,"is_preprint":false},{"pmid":"11164892","id":"PMC_11164892","title":"IL-4 induces serine phosphorylation of the STAT6 transactivation domain in B lymphocytes.","date":"2000","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/11164892","citation_count":48,"is_preprint":false},{"pmid":"25145352","id":"PMC_25145352","title":"Grail controls Th2 cell development by targeting STAT6 for degradation.","date":"2014","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/25145352","citation_count":47,"is_preprint":false},{"pmid":"11714739","id":"PMC_11714739","title":"STAT4 and STAT6 regulate systemic inflammation and protect against lethal endotoxemia.","date":"2001","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/11714739","citation_count":47,"is_preprint":false},{"pmid":"23844087","id":"PMC_23844087","title":"TLR3-induced placental miR-210 down-regulates the STAT6/interleukin-4 pathway.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23844087","citation_count":47,"is_preprint":false},{"pmid":"36216080","id":"PMC_36216080","title":"A germline STAT6 gain-of-function variant is associated with early-onset allergies.","date":"2022","source":"The Journal of allergy and clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/36216080","citation_count":46,"is_preprint":false},{"pmid":"18292582","id":"PMC_18292582","title":"IL-4 is a critical determinant in the generation of allergic inflammation initiated by a constitutively active Stat6.","date":"2008","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/18292582","citation_count":46,"is_preprint":false},{"pmid":"36757802","id":"PMC_36757802","title":"IL-13RA2 downregulation in fibroblasts promotes keloid fibrosis via JAK/STAT6 activation.","date":"2023","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/36757802","citation_count":42,"is_preprint":false},{"pmid":"28205598","id":"PMC_28205598","title":"Lyn regulates mucus secretion and MUC5AC via the STAT6 signaling pathway during allergic airway inflammation.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/28205598","citation_count":42,"is_preprint":false},{"pmid":"28385737","id":"PMC_28385737","title":"Lack of STAT6 Attenuates Inflammation and Drives Protection against Early Steps of Colitis-Associated Colon Cancer.","date":"2017","source":"Cancer immunology research","url":"https://pubmed.ncbi.nlm.nih.gov/28385737","citation_count":42,"is_preprint":false},{"pmid":"28819278","id":"PMC_28819278","title":"Interleukin 4 induces apoptosis of acute myeloid leukemia cells in a Stat6-dependent manner.","date":"2017","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/28819278","citation_count":42,"is_preprint":false},{"pmid":"31041750","id":"PMC_31041750","title":"Analysis of IL-4/STAT6 Signaling in Macrophages.","date":"2019","source":"Methods in molecular biology (Clifton, N.J.)","url":"https://pubmed.ncbi.nlm.nih.gov/31041750","citation_count":41,"is_preprint":false},{"pmid":"19519791","id":"PMC_19519791","title":"Polymorphisms in the STAT6 gene and their association with carcass traits in feedlot cattle.","date":"2009","source":"Animal genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19519791","citation_count":41,"is_preprint":false},{"pmid":"11374866","id":"PMC_11374866","title":"Binding of BAZF and Bc16 to STAT6-binding DNA sequences.","date":"2001","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/11374866","citation_count":39,"is_preprint":false},{"pmid":"21751242","id":"PMC_21751242","title":"Interleukin-4 inhibits RANKL-induced NFATc1 expression via STAT6: a novel mechanism mediating its blockade of osteoclastogenesis.","date":"2011","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21751242","citation_count":37,"is_preprint":false},{"pmid":"30665041","id":"PMC_30665041","title":"IL-37 attenuates allergic process via STAT6/STAT3 pathways in murine allergic rhinitis.","date":"2019","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/30665041","citation_count":36,"is_preprint":false},{"pmid":"21242523","id":"PMC_21242523","title":"STAT6 expression in multiple cell types mediates the cooperative development of allergic airway disease.","date":"2011","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/21242523","citation_count":36,"is_preprint":false},{"pmid":"9845517","id":"PMC_9845517","title":"Stat6 inhibits human interleukin-4 promoter activity in T cells.","date":"1998","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/9845517","citation_count":36,"is_preprint":false},{"pmid":"37316763","id":"PMC_37316763","title":"Autosomal Dominant STAT6 Gain of Function Causes Severe Atopy Associated with Lymphoma.","date":"2023","source":"Journal of clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/37316763","citation_count":34,"is_preprint":false},{"pmid":"10229091","id":"PMC_10229091","title":"STAT6-independent production of IL-4 by mast cells.","date":"1999","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/10229091","citation_count":34,"is_preprint":false},{"pmid":"11067913","id":"PMC_11067913","title":"Role of STAT4 and STAT6 signaling in allograft rejection and CTLA4-Ig-mediated tolerance.","date":"2000","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/11067913","citation_count":33,"is_preprint":false},{"pmid":"37941008","id":"PMC_37941008","title":"Efferocytosis is restricted by axon guidance molecule EphA4 via ERK/Stat6/MERTK signaling following brain injury.","date":"2023","source":"Journal of neuroinflammation","url":"https://pubmed.ncbi.nlm.nih.gov/37941008","citation_count":30,"is_preprint":false},{"pmid":"33652833","id":"PMC_33652833","title":"STAT6 Signaling Mediates PPARγ Activation and Resolution of Acute Sterile Inflammation in Mice.","date":"2021","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/33652833","citation_count":30,"is_preprint":false},{"pmid":"20498360","id":"PMC_20498360","title":"Live cell imaging reveals continuous STAT6 nuclear trafficking.","date":"2010","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/20498360","citation_count":30,"is_preprint":false},{"pmid":"12426308","id":"PMC_12426308","title":"Protein phosphatase 2A (PP2A) regulates interleukin-4-mediated STAT6 signaling.","date":"2002","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12426308","citation_count":29,"is_preprint":false},{"pmid":"33153718","id":"PMC_33153718","title":"TRPM7 modulates macrophage polarization by STAT1/STAT6 pathways in RAW264.7 cells.","date":"2020","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/33153718","citation_count":29,"is_preprint":false},{"pmid":"18296848","id":"PMC_18296848","title":"IL-13 attenuates vascular tube formation via JAK2-STAT6 pathway.","date":"2008","source":"Circulation journal : official journal of the Japanese Circulation Society","url":"https://pubmed.ncbi.nlm.nih.gov/18296848","citation_count":29,"is_preprint":false},{"pmid":"10072514","id":"PMC_10072514","title":"IL-4 preferentially activates a novel STAT6 isoform in mast cells.","date":"1999","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/10072514","citation_count":29,"is_preprint":false},{"pmid":"16914450","id":"PMC_16914450","title":"Characterization of RNA helicase A as component of STAT6-dependent enhanceosome.","date":"2006","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/16914450","citation_count":29,"is_preprint":false},{"pmid":"30076218","id":"PMC_30076218","title":"Hierarchical control of interleukin 13 (IL-13) signals in lung fibroblasts by STAT6 and SOX11.","date":"2018","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/30076218","citation_count":28,"is_preprint":false},{"pmid":"20608912","id":"PMC_20608912","title":"Gene silencing of STAT6 with siRNA ameliorates contact hypersensitivity and allergic rhinitis.","date":"2011","source":"Allergy","url":"https://pubmed.ncbi.nlm.nih.gov/20608912","citation_count":27,"is_preprint":false},{"pmid":"36359867","id":"PMC_36359867","title":"Curcumin Reprograms TAMs from a Protumor Phenotype towards an Antitumor Phenotype via Inhibiting MAO-A/STAT6 Pathway.","date":"2022","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/36359867","citation_count":27,"is_preprint":false},{"pmid":"33017719","id":"PMC_33017719","title":"TRAF6 promotes IL-4-induced M2 macrophage activation by stabilizing STAT6.","date":"2020","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/33017719","citation_count":26,"is_preprint":false},{"pmid":"14725901","id":"PMC_14725901","title":"Interleukin-4 elicits apoptosis of developing mast cells via a Stat6-dependent mitochondrial pathway.","date":"2004","source":"Experimental hematology","url":"https://pubmed.ncbi.nlm.nih.gov/14725901","citation_count":26,"is_preprint":false},{"pmid":"30675252","id":"PMC_30675252","title":"MicroRNA-135a induces prostate cancer cell apoptosis via inhibition of STAT6.","date":"2018","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/30675252","citation_count":26,"is_preprint":false},{"pmid":"39188021","id":"PMC_39188021","title":"STAT4 and STAT6, their role in cellular and humoral immunity and in diverse human diseases.","date":"2024","source":"International reviews of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/39188021","citation_count":25,"is_preprint":false},{"pmid":"33662403","id":"PMC_33662403","title":"The roles of STAT6 in regulating B cell fate, activation, and function.","date":"2021","source":"Immunology letters","url":"https://pubmed.ncbi.nlm.nih.gov/33662403","citation_count":25,"is_preprint":false},{"pmid":"29090910","id":"PMC_29090910","title":"Targeted Inhibition of the NCOA1/STAT6 Protein-Protein Interaction.","date":"2017","source":"Journal of the American Chemical Society","url":"https://pubmed.ncbi.nlm.nih.gov/29090910","citation_count":25,"is_preprint":false},{"pmid":"32360783","id":"PMC_32360783","title":"Interleukin-4 stimulates lipogenesis in meibocytes by activating the STAT6/PPARγ signaling pathway.","date":"2020","source":"The ocular surface","url":"https://pubmed.ncbi.nlm.nih.gov/32360783","citation_count":25,"is_preprint":false},{"pmid":"33264064","id":"PMC_33264064","title":"Rhinovirus-induced CCL17 and CCL22 in Asthma Exacerbations and Differential Regulation by STAT6.","date":"2021","source":"American journal of respiratory cell and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/33264064","citation_count":24,"is_preprint":false},{"pmid":"22045870","id":"PMC_22045870","title":"Transcriptional activation of the IL31 gene by NFAT and STAT6.","date":"2011","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/22045870","citation_count":24,"is_preprint":false},{"pmid":"27743998","id":"PMC_27743998","title":"Zebrafish STAT6 negatively regulates IFNφ1 production by attenuating the kinase activity of TANK-binding kinase 1.","date":"2016","source":"Developmental and comparative immunology","url":"https://pubmed.ncbi.nlm.nih.gov/27743998","citation_count":23,"is_preprint":false},{"pmid":"22017802","id":"PMC_22017802","title":"Association of ORMDL3, STAT6 and TBXA2R gene polymorphisms with asthma.","date":"2011","source":"International journal of immunogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/22017802","citation_count":23,"is_preprint":false},{"pmid":"10882411","id":"PMC_10882411","title":"STAT6 is required for the regulation of IL-4-induced cytoskeletal events in B cells.","date":"2000","source":"International immunology","url":"https://pubmed.ncbi.nlm.nih.gov/10882411","citation_count":23,"is_preprint":false},{"pmid":"39107960","id":"PMC_39107960","title":"S100A9 deletion in microglia/macrophages ameliorates brain injury through the STAT6/PPARγ pathway in ischemic stroke.","date":"2024","source":"CNS neuroscience & therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/39107960","citation_count":22,"is_preprint":false},{"pmid":"39701329","id":"PMC_39701329","title":"Irisin reprograms microglia through activation of STAT6 and prevents cognitive dysfunction after surgery in mice.","date":"2024","source":"Brain, behavior, and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/39701329","citation_count":22,"is_preprint":false},{"pmid":"23383189","id":"PMC_23383189","title":"Live-cell imaging of the association of STAT6-GFP with mitochondria.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23383189","citation_count":22,"is_preprint":false},{"pmid":"29466035","id":"PMC_29466035","title":"Inhibition of STAT6/Anoctamin-1 Activation Suppresses Proliferation and Invasion of Gastric Cancer Cells.","date":"2018","source":"Cancer biotherapy & radiopharmaceuticals","url":"https://pubmed.ncbi.nlm.nih.gov/29466035","citation_count":21,"is_preprint":false},{"pmid":"11532018","id":"PMC_11532018","title":"Specific inhibition of interleukin-4-dependent Stat6 activation by an intracellularly delivered peptide.","date":"2001","source":"European journal of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11532018","citation_count":21,"is_preprint":false},{"pmid":"9686563","id":"PMC_9686563","title":"A conditionally active form of STAT6 can mimic certain effects of IL-4.","date":"1998","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/9686563","citation_count":21,"is_preprint":false},{"pmid":"35851155","id":"PMC_35851155","title":"PARP14 is a novel target in STAT6 mutant follicular lymphoma.","date":"2022","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/35851155","citation_count":20,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":47686,"output_tokens":8693,"usd":0.136727},"stage2":{"model":"claude-opus-4-6","input_tokens":12692,"output_tokens":4744,"usd":0.27309},"total_usd":0.409817,"stage1_batch_id":"msgbatch_011rkcQdVV1RaFq9XhcG6df6","stage2_batch_id":"msgbatch_01RzgrJafdF4EWHhj5mNi6dh","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1996,\n      \"finding\": \"STAT6 is essential for IL-4 signaling: Stat6-deficient mice show abolished IL-4-induced B-cell proliferation, impaired T-cell proliferative responses, and loss of CD23/MHC class II upregulation, demonstrating STAT6 is the central mediator of IL-4-mediated biological responses.\",\n      \"method\": \"Gene targeting (knockout mice), functional immune assays\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — foundational KO study with multiple orthogonal phenotypic readouts, replicated widely\",\n      \"pmids\": [\"8602263\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"STAT6 is also required for IL-13 signaling in macrophages: STAT6-deficient mice show impaired IL-13-induced morphological changes, MHC class II upregulation, and failure to decrease nitric oxide production, indicating IL-4 and IL-13 share the STAT6 signaling pathway.\",\n      \"method\": \"STAT6 knockout mice, macrophage functional assays\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean KO with multiple defined cellular phenotypes\",\n      \"pmids\": [\"8871614\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"The carboxyl terminus of STAT6 contains a 140-amino-acid proline-rich transcriptional activation domain required for IL-4-induced gene expression; truncation mutants lacking this domain cannot activate transcription and act as dominant negatives.\",\n      \"method\": \"Gal4 fusion constructs, deletion mutant analysis, reporter gene assays\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — domain mapping with mutagenesis and functional reporter assays\",\n      \"pmids\": [\"9233621\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"The STAT6 SH2 domain mediates both receptor binding (to tyrosine-phosphorylated IL-4Rα) and dimerization; mutational analysis identified residues specifically required for each function, and the SH2 domain structure resembles but differs from Src SH2 at C-terminal ends.\",\n      \"method\": \"Alanine-scanning mutagenesis, phosphopeptide binding assays, DNA binding assays, expression in mammalian and insect cells\",\n      \"journal\": \"Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — extensive mutational analysis with multiple functional readouts\",\n      \"pmids\": [\"9651359\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"A conditionally active STAT6 fusion protein (STAT6:ER*) activates STAT6-regulated gene expression (CD23 induction, reporter activation) independently of detectable tyrosine phosphorylation, suggesting STAT6 can signal through phosphorylation-independent mechanisms.\",\n      \"method\": \"Conditional fusion protein (hormone-binding domain), reporter assays, flow cytometry\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — single study with defined mechanistic outcome using engineered construct\",\n      \"pmids\": [\"9686563\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"STAT6 interacts with the coactivator p300/CBP through its C-terminal transactivation domain; this interaction is required for IL-4-induced transcription, as E1A (which sequesters p300/CBP) blocks IL-4 responses, and CBP interaction domain maps to CBP aa 1850–2176.\",\n      \"method\": \"Co-immunoprecipitation, mammalian two-hybrid assay, E1A repression assay, reporter gene assays\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — reciprocal Co-IP plus functional repression assays, multiple orthogonal methods\",\n      \"pmids\": [\"10373589\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"IFN-α activates STAT6 in B cells in a cell-type-specific manner, leading to formation of novel STAT2:STAT6 heterodimeric complexes (including an ISGF3-like complex with STAT2, STAT6, and p48) that can target IFN-responsive elements.\",\n      \"method\": \"Tyrosine phosphorylation assays, EMSA, co-immunoprecipitation\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — single lab, multiple biochemical methods demonstrating novel complex formation\",\n      \"pmids\": [\"10490982\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"STAT6 mediates IL-4-induced repression of NF-κB- and STAT1-dependent transcription via distinct mechanisms: NF-κB repression requires STAT6 DNA binding (H415A mutation abolishes it) and involves CBP sequestration; STAT1 repression requires STAT6 transactivation domain but is DNA-binding-independent.\",\n      \"method\": \"Transient transfection in STAT6-deficient HEK293 cells, STAT6 point and deletion mutants, reporter assays\",\n      \"journal\": \"Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstitution in STAT6-null cells with mutagenesis and multiple reporter systems\",\n      \"pmids\": [\"10982806\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"IL-4 induces serine phosphorylation of STAT6 specifically within its transactivation domain (residues 719–789), independently of tyrosine phosphorylation at Y641 and independently of the IRS/PI3K, PKC, or MAPK pathways.\",\n      \"method\": \"Phosphoamino acid analysis, 2D phosphopeptide mapping, STAT6 deletion and point mutants in B cells\",\n      \"journal\": \"Molecular immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — biochemical mapping with multiple mutants and orthogonal phosphorylation analyses\",\n      \"pmids\": [\"11164892\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"A gain-of-function STAT6 mutant (STAT6VT) with two SH2 domain amino acid changes undergoes constitutive tyrosine phosphorylation, DNA binding, and transcriptional activation independently of IL-4, via an IL-4-independent kinase.\",\n      \"method\": \"Site-directed mutagenesis, expression in JAK1/JAK3-deficient cells, DNA binding assay, reporter assay\",\n      \"journal\": \"Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — structure-function mutagenesis with mechanistic validation in kinase-deficient cells\",\n      \"pmids\": [\"10747856\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"IL-4 and IL-13 inhibit NO production in macrophages via STAT6-dependent upregulation of arginase I, which depletes arginine (the iNOS substrate), rather than by directly inhibiting iNOS expression or activity.\",\n      \"method\": \"STAT6-knockout macrophages, arginase activity assay, arginine supplementation rescue, NO production assay, Toxoplasma killing assay\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — KO with multiple orthogonal assays and substrate rescue experiment\",\n      \"pmids\": [\"11160269\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"IL-4-induced STAT6 blocks osteoclastogenesis by inhibiting NF-κB DNA binding; exogenous STAT6 protein directly inhibits NF-κB/DNA interaction, and this blockade is absent in STAT6-/- mice but rescued by exogenous STAT6 addition.\",\n      \"method\": \"STAT6 KO mice, EMSA with unlabeled STAT6 competitor, exogenous protein addition, osteoclastogenesis assay\",\n      \"journal\": \"Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — KO rescue with exogenous protein plus in vitro DNA binding competition\",\n      \"pmids\": [\"11390419\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"STAT6 is required for IL-4-induced cytoskeletal changes in B cells (spreading, polarization, microvilli formation) but is less critical for adhesion, indicating STAT6-dependent gene expression regulates cytoskeletal remodeling.\",\n      \"method\": \"STAT6-KO B cells, light and electron microscopy, adhesion assays\",\n      \"journal\": \"International immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — KO with defined morphological readouts, single study\",\n      \"pmids\": [\"10882411\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"p100 protein (SN-like/tudor domain) is a coactivator for STAT6 that interacts with STAT6's transactivation domain, enhances STAT6-mediated transcription, and bridges STAT6 to RNA polymerase II.\",\n      \"method\": \"In vitro pulldown, Co-IP in vivo, reporter assays, RNA pol II co-immunoprecipitation\",\n      \"journal\": \"EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal Co-IP plus in vitro binding plus functional transcription assays\",\n      \"pmids\": [\"12234934\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Ym1 gene expression in macrophages is induced by IL-4 through STAT6-binding response elements in its promoter; STAT6 participates as an obligate component of protein complexes binding to these sites, confirmed by nuclear extracts from STAT6-deficient macrophages.\",\n      \"method\": \"Microarray, promoter reporter assays, EMSA with STAT6-null nuclear extracts, in vivo allergic peritonitis model\",\n      \"journal\": \"Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — functional promoter mapping with STAT6-null confirmation and in vivo validation\",\n      \"pmids\": [\"12215441\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Protein phosphatase 2A (PP2A) regulates STAT6 function: PP2A inhibition induces serine phosphorylation of STAT6 and severely inhibits its DNA binding without affecting JAK1 or tyrosine phosphorylation, placing PP2A downstream of JAKs.\",\n      \"method\": \"PP2A inhibitor treatment, phosphorylation assays, EMSA\",\n      \"journal\": \"Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pharmacological approach with clear mechanistic separation of tyrosine vs. serine phosphorylation effects\",\n      \"pmids\": [\"12426308\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"RNA helicase A (RHA) is a component of the STAT6 transcription complex; it does not directly interact with STAT6 but is recruited via p100 to form a STAT6-p100-RHA ternary complex on IL-4-responsive promoters and enhances IL-4-induced transcription.\",\n      \"method\": \"In vitro and in vivo binding assays, chromatin immunoprecipitation, RNAi knockdown, reporter assay\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — ChIP plus RNAi plus multiple binding assays demonstrating ternary complex\",\n      \"pmids\": [\"16914450\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"CoaSt6 (collaborator of Stat6), a PARP-like protein, associates with STAT6 and possesses poly(ADP-ribosyl)ation activity; its catalytic activity is required for enhancement of STAT6-mediated transcription, and PARP inhibition blocks IL-4-dependent transcription.\",\n      \"method\": \"PARP enzymatic assay, catalytically inactive mutant, PARP chemical inhibitor, reporter assay, ADP-ribosylation of p100\",\n      \"journal\": \"Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro enzymatic assay plus mutagenesis plus pharmacological inhibition\",\n      \"pmids\": [\"17478423\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Kaempferol inhibits IL-4-induced STAT6 activation by specifically blocking the kinase activity of JAK3 (not JAK1), and has no effect in non-hematopoietic cell lines lacking JAK3, confirming JAK3 as the specific target.\",\n      \"method\": \"In vitro kinase assay, phosphorylation analysis, cell lines lacking JAK3\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro kinase assay plus genetic cell-line confirmation\",\n      \"pmids\": [\"17785825\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"STAT6 continuously shuttles into the nucleus independently of tyrosine phosphorylation via the coiled-coil domain and the classical importin-α/importin-β1 system; nuclear accumulation occurs after cytokine stimulation due to phosphorylation-dependent DNA binding rather than increased import.\",\n      \"method\": \"Live-cell imaging, FRAP, photobleaching, importin pathway inhibition, domain deletion analysis\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — live imaging with FRAP plus domain analysis, multiple orthogonal approaches\",\n      \"pmids\": [\"20498360\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"STAT6 constitutively associates with mitochondria independently of tyrosine phosphorylation (SH2 domain and Y641); a truncated STAT6 lacking the SH2 domain still accumulates in MitoTracker-positive mitochondria.\",\n      \"method\": \"Live-cell imaging, immunofluorescence, electron microscopy, GFP fusion constructs, digitonin fractionation\",\n      \"journal\": \"PLoS ONE\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple imaging modalities and truncation constructs, single lab\",\n      \"pmids\": [\"23383189\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Grail (an E3 ubiquitin ligase) interacts with STAT6 and targets it for ubiquitination and proteasomal degradation, forming a negative feedback loop in Th2 cells that limits IL-4 receptor α and STAT6 levels.\",\n      \"method\": \"Co-IP, ubiquitination assay, Grail-KO mice, Th2 cell functional assays\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP plus ubiquitination assay plus KO phenotype, multiple orthogonal methods\",\n      \"pmids\": [\"25145352\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Crystal structure of phosphorylated STAT6 core fragment homodimer bound to N3 and N4 DNA reveals a dramatic conformational change upon DNA binding; H415 in the DNA-binding domain discriminates N4 from N3 sites, and H415N mutation decreases N4 affinity and increases N3 affinity both in vitro and in vivo.\",\n      \"method\": \"X-ray crystallography, molecular dynamics simulation, SAXS, mutagenesis, in vitro and in vivo DNA binding assays\",\n      \"journal\": \"PNAS\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure plus mutagenesis with functional validation, multiple methods\",\n      \"pmids\": [\"27803324\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"NCOA1 (nuclear receptor coactivator 1) is required for STAT6 transcriptional activity; a stapled helical peptide disrupts the NCOA1/STAT6 protein-protein interaction and represses STAT6-mediated transcription, with first crystal structure of stapled peptide-NCOA1 complex solved.\",\n      \"method\": \"Stapled peptide design, crystal structure of peptide-NCOA1 complex, reporter assay, Co-IP disruption\",\n      \"journal\": \"Journal of the American Chemical Society\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure plus functional disruption assay\",\n      \"pmids\": [\"29090910\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"IL-4-activated STAT6 directly represses inflammatory enhancers through an HDAC3-dependent mechanism on a subset of genes, reducing p300 and RNA Pol II binding, enhancer RNA expression, H3K27ac, and chromatin accessibility; STAT6-repressed enhancers overlap with the NF-κB p65 cistrome and exhibit decreased LPS responsiveness.\",\n      \"method\": \"ChIP-seq, ATAC-seq, RNA-seq in macrophages, HDAC3 inhibition, STAT6-KO mice, in vitro/in vivo IL-4 polarization\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — genome-wide multimodal epigenomic approach with KO validation\",\n      \"pmids\": [\"29343442\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"STAT6 is acetylated at Lys383 by CBP during macrophage activation; Trim24 (a CBP-associated E3 ligase) promotes STAT6 acetylation by ubiquitinating CBP at Lys119 to facilitate CBP recruitment to STAT6. Acetylation of STAT6 suppresses M2 polarization; Trim24 loss inhibits acetylation and promotes M2 polarization.\",\n      \"method\": \"Mass spectrometry identification of acetylation site, Co-IP, ubiquitination assay, Trim24 KO mice, human/mouse macrophage assays\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — MS-identified PTM, mechanistic Co-IP, KO validation in two species\",\n      \"pmids\": [\"31554795\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"STAT6 activation in macrophages induces expression of the efferocytic ligand Gas6, which mediates clearance of apoptotic neutrophils; Gas6-depleted macrophages fail to clear apoptotic cells, and adoptive transfer of Gas6-expressing macrophages rescues efferocytosis in STAT6-KO mice.\",\n      \"method\": \"STAT6-KO mice, adoptive transfer, in vitro efferocytosis assay, bone marrow-derived macrophage priming\",\n      \"journal\": \"PNAS\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo KO, adoptive transfer rescue, and in vitro mechanistic dissection\",\n      \"pmids\": [\"31363052\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"TRAF6 stabilizes STAT6 protein by reducing K48-linked ubiquitination that would otherwise lead to proteasomal degradation; TRAF6 promotes K63-linked ubiquitination of STAT6 but this E3 ligase activity is dispensable for STAT6 stabilization, while TRAF6-STAT6 interaction requires the TRAF6 C domain.\",\n      \"method\": \"Co-IP, ubiquitination assay, TRAF6 KO/KD macrophages, STAT6 protein stability assay\",\n      \"journal\": \"Molecular immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP plus ubiquitination assay with K48/K63 linkage discrimination and domain mapping\",\n      \"pmids\": [\"33017719\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"TRAF3 promotes STAT6 ubiquitination at K450 (and K129) to enhance its transcriptional activity and M2 macrophage polarization; TRAF3 deficiency decreases STAT6 ubiquitination and abolishes IL-4-induced M2 polarization.\",\n      \"method\": \"Quantitative ubiquitomics (MS), site-directed mutagenesis (K450 mutation), ubiquitination assay, luciferase assay, TRAF3-KO mice melanoma model\",\n      \"journal\": \"Cell death and differentiation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — MS-based ubiquitomics plus mutagenesis plus functional reporter assays plus in vivo KO\",\n      \"pmids\": [\"37474750\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"STAT6 inhibits ferroptosis in lung epithelial cells by competitively binding to CBP, thereby inhibiting CBP-mediated acetylation of p53 and transcriptionally restoring SLC7A11 (a ferroptosis suppressor) expression.\",\n      \"method\": \"STAT6 conditional KO mice, STAT6 overexpression, Co-IP (STAT6-CBP), p53 acetylation assay, SLC7A11 expression analysis\",\n      \"journal\": \"Cell death and disease\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — KO plus OE plus Co-IP plus acetylation assay, multiple orthogonal methods\",\n      \"pmids\": [\"35668064\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Stat6 is required for Th2-mediated intestinal goblet cell hyperplasia during nematode infection; STAT6-deficient mice fail to generate infection-induced goblet cell hyperplasia, correlating with impaired IL-4/IL-13 production and reduced parasite expulsion.\",\n      \"method\": \"STAT6-KO mice, parasite infection model, goblet cell quantification\",\n      \"journal\": \"Parasite immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — clean KO with defined cellular phenotype, single lab\",\n      \"pmids\": [\"11136476\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"A peptide derived from the STAT6-binding region of IL-4Rα, when delivered intracellularly, completely inhibits IL-4-dependent tyrosine phosphorylation of STAT6 and STAT6-dependent transcription, without affecting STAT5 phosphorylation.\",\n      \"method\": \"Cell-permeable peptide delivery, phosphorylation assay, reporter gene assay\",\n      \"journal\": \"European journal of biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic peptide inhibition with specificity controls\",\n      \"pmids\": [\"11532018\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"STAT3 and STAT6 synergize to upregulate cathepsin secretion by macrophages via engagement of IRE1α (UPR sensor); pharmacological inhibition of IRE1α blocks cathepsin secretion and macrophage-mediated cancer cell invasion.\",\n      \"method\": \"Whole-genome expression analysis, IRE1α pharmacological inhibition, STAT3/STAT6 genetic deletion, invasion assay\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genome-wide analysis plus pharmacological and genetic intervention, multiple readouts\",\n      \"pmids\": [\"27626662\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"B-cell-intrinsic STAT6 signaling is required for germinal center formation; STAT6 deficiency in B cells results in failure to downregulate the chemotactic receptor Gpr183/Ebi2, which is essential for proper GC B-cell positioning and differentiation.\",\n      \"method\": \"Conditional B-cell STAT6 deficiency (BM chimeras), helminth infection model, flow cytometry, GC B-cell analysis\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — cell-type-specific KO with mechanistic identification of Gpr183 as downstream target\",\n      \"pmids\": [\"24777733\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"STAT6 mediates IL-4/IL-13-induced downregulation of skin barrier proteins loricrin and involucrin in keratinocytes; STAT6 transgenic mice are deficient in loricrin and involucrin expression.\",\n      \"method\": \"Primary keratinocyte cultures, siRNA/transgenic mouse model, gene/protein expression analysis\",\n      \"journal\": \"Clinical immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — transgenic model plus in vitro cytokine treatment, mechanistic pathway identified\",\n      \"pmids\": [\"18166499\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Germline gain-of-function STAT6 mutation (E372K in DNA-binding domain) augments both basal and cytokine-induced STAT6 phosphorylation, causes preferential nuclear localization, and drives severe allergic disease; JAK1/2 inhibitor ruxolitinib reverses STAT6 hyperresponsiveness.\",\n      \"method\": \"Whole-exome sequencing, EMSA, luciferase assay, Western blot, immunofluorescence, JAK inhibitor treatment, gastric organoids\",\n      \"journal\": \"Journal of allergy and clinical immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal functional assays in patient and engineered cells\",\n      \"pmids\": [\"36758835\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Germline STAT6 gain-of-function variant (E377K in DNA-binding domain) results in spontaneous STAT6 transcriptional activity, strong preference for nuclear localization, increased DNA binding affinity, and constitutive activation of downstream signaling in gastric organoids.\",\n      \"method\": \"Exome sequencing, EMSA, luciferase assay, immunofluorescence, gastric organoids, Western blot\",\n      \"journal\": \"Journal of allergy and clinical immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple functional assays in patient cells plus organoid model\",\n      \"pmids\": [\"36216080\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"IL-4-induced STAT6 and KLF4 implement M2 macrophage polarization via induction of MCPIP, which inhibits NF-κB activation (deubiquitinase activity) and drives M2 polarization through its RNase activity causing sequential ROS, ER stress, and autophagy induction.\",\n      \"method\": \"Murine macrophages, myeloid-specific MCPIP overexpression/KO mice, M1/M2 polarization assays\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo KO and OE models with defined molecular mechanism\",\n      \"pmids\": [\"25934862\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"STAT6 NF-κB inhibition involves inhibition of IκBα phosphorylation and degradation (blocking NF-κB nuclear import), while glucocorticoid receptor acts by increasing p65 nuclear export rate; STAT6 and GR thus inhibit NF-κB by distinct mechanisms.\",\n      \"method\": \"Fluorescent fusion protein live imaging, NF-κB reporter assay, IκBα phosphorylation assay\",\n      \"journal\": \"Journal of cell science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — live imaging with functional reporter assays, mechanistic dissection of two pathways\",\n      \"pmids\": [\"12734399\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Lyn kinase negatively regulates IL-4/IL-13-induced STAT6 activation and MUC5AC expression; Lyn overexpression decreases STAT6 phosphorylation and chromatin binding to the MUC5AC promoter, while Lyn knockdown increases STAT6 and MUC5AC levels.\",\n      \"method\": \"Chromatin immunoprecipitation, overexpression/knockdown in cells and OVA-challenged mice, STAT6 phosphorylation assay\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP plus in vivo mouse model, single lab\",\n      \"pmids\": [\"28205598\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"IL-4 stimulates lipogenesis in meibomian gland epithelial cells through a STAT6/PPARγ signaling pathway; STAT6 phosphorylation inhibition suppresses IL-4-mediated lipid synthesis and PPARγ/SREBP-1 expression.\",\n      \"method\": \"IL-4 treatment with STAT6 inhibitor, Western blot, lipid staining, HGMEC culture\",\n      \"journal\": \"Ocular surface\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pharmacological inhibition with defined signaling pathway and lipid readout\",\n      \"pmids\": [\"32360783\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Gain-of-function STAT6 mutations in follicular lymphoma (DNA-binding domain) enhance IL-4-induced transcription at the PARP14 promoter; STAT6MUT binds PARP14 promoter (not STAT6WT by ChIP), creating a self-reinforcing circuit; PARP14 knockdown or PARP inhibition abrogates the STAT6MUT gain-of-function phenotype.\",\n      \"method\": \"qChIP, reporter assay, RNA-seq, CRISPR KD, PARP inhibitor treatment, pre-B CFU assay\",\n      \"journal\": \"Leukemia\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — ChIP plus reporter plus genetic rescue with multiple orthogonal approaches\",\n      \"pmids\": [\"35851155\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"STAT6 is a latent transcription factor activated primarily by IL-4 and IL-13 via JAK-mediated tyrosine phosphorylation (at Y641) of its SH2 domain, which drives homodimerization, nuclear import via importin-α/β, and DNA binding at N4 elements through a unique H415 residue; once nuclear, STAT6 recruits coactivators p300/CBP, p100, RHA, NCOA1, and CoaSt6 (a PARP) to activate target genes (arginase I, Gas6, Ym1, MUC5AC, etc.), and simultaneously represses inflammatory enhancers via HDAC3 and NF-κB sequestration; STAT6 activity is fine-tuned by acetylation at K383 by CBP (suppressive), ubiquitination at K450 by TRAF3 (activating), proteasomal degradation via Grail/TRAF6-mediated ubiquitination, and dephosphorylation by PP2A, while gain-of-function mutations in its DNA-binding domain cause constitutive signaling and severe allergic disease.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"STAT6 is a latent transcription factor that serves as the central mediator of IL-4 and IL-13 signaling, governing Th2 immunity, alternative macrophage activation, and allergic inflammation. Upon cytokine stimulation, JAK3-mediated tyrosine phosphorylation at Y641 promotes SH2-domain-dependent homodimerization and DNA binding to N4-spaced GAS elements — a specificity conferred by H415 in the DNA-binding domain — while STAT6 continuously shuttles into the nucleus via importin-α/β through its coiled-coil domain independently of phosphorylation, with nuclear accumulation driven by DNA retention [PMID:8602263, PMID:9651359, PMID:27803324, PMID:20498360]. Nuclear STAT6 recruits a multicomponent coactivator assembly (p300/CBP, p100, RNA helicase A, NCOA1, and the PARP-family protein CoaSt6) to activate target genes including arginase I, Ym1, Gas6, and MUC5AC, while simultaneously repressing inflammatory enhancers through HDAC3-dependent chromatin deacetylation and inhibition of NF-κB DNA binding via IκBα stabilization and CBP sequestration [PMID:10373589, PMID:12234934, PMID:16914450, PMID:29090910, PMID:29343442, PMID:10982806]. STAT6 protein levels and activity are tuned by suppressive acetylation at K383 by CBP (promoted by Trim24-mediated CBP ubiquitination), activating ubiquitination at K450 by TRAF3, stabilization by TRAF6 through blockade of K48-linked ubiquitination, and proteasomal degradation directed by the E3 ligase Grail [PMID:31554795, PMID:37474750, PMID:33017719, PMID:25145352]. Germline gain-of-function mutations in the STAT6 DNA-binding domain (E372K, E377K) cause constitutive nuclear localization and transcriptional activation, resulting in severe early-onset allergic disease [PMID:36758835, PMID:36216080].\",\n  \"teleology\": [\n    {\n      \"year\": 1996,\n      \"claim\": \"Establishing STAT6 as the non-redundant mediator of IL-4 and IL-13 biological responses resolved which STAT family member transduces these cytokine signals in vivo.\",\n      \"evidence\": \"Stat6-knockout mice showing abolished IL-4-induced B-cell proliferation, CD23/MHC II upregulation, and IL-13-induced macrophage responses\",\n      \"pmids\": [\"8602263\", \"8871614\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contribution of STAT6 to IL-4 versus IL-13 signaling in individual cell types not fully dissected\", \"Downstream transcriptional targets not yet identified at this stage\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Mapping the STAT6 domain architecture — a C-terminal proline-rich transactivation domain and an SH2 domain with separable receptor-binding and dimerization functions — defined the structural basis for signal transduction from receptor to DNA.\",\n      \"evidence\": \"Gal4 fusion/deletion mutant reporter assays and systematic alanine-scanning mutagenesis of the SH2 domain\",\n      \"pmids\": [\"9233621\", \"9651359\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Three-dimensional structure not yet available\", \"Serine phosphorylation contributions to transactivation unknown\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Identification of p300/CBP as a STAT6 coactivator and discovery that IFN-α can activate STAT6 in B cells via STAT2:STAT6 heterodimers expanded the mechanistic picture beyond the IL-4/IL-13 paradigm.\",\n      \"evidence\": \"Co-IP and mammalian two-hybrid mapping CBP interaction to STAT6 TAD; EMSA and Co-IP showing STAT2:STAT6 heterodimers in IFN-α-treated B cells\",\n      \"pmids\": [\"10373589\", \"10490982\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of CBP-STAT6 interaction not resolved\", \"Physiological relevance of STAT2:STAT6 in IFN signaling not confirmed in vivo\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Dissection of how STAT6 represses NF-κB (via DNA-binding-dependent CBP competition and IκBα stabilization) and STAT1 (via TAD-dependent, DNA-binding-independent mechanisms) revealed STAT6 as an active transcriptional repressor, not merely an activator.\",\n      \"evidence\": \"STAT6 point mutants (H415A) in STAT6-null HEK293 reconstitution, live-cell NF-κB reporter imaging, IκBα phosphorylation assays\",\n      \"pmids\": [\"10982806\", \"12734399\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Genome-wide repression targets unknown\", \"Whether repression requires new protein synthesis or is direct was unresolved\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Identification of serine phosphorylation within the STAT6 TAD (residues 719–789) occurring independently of Y641 and the IRS/PI3K/MAPK pathways, plus the observation that PP2A regulates DNA binding via serine dephosphorylation, revealed a second layer of post-translational regulation.\",\n      \"evidence\": \"2D phosphopeptide mapping with STAT6 deletion mutants; PP2A inhibitor treatment separating serine from tyrosine phosphorylation effects\",\n      \"pmids\": [\"11164892\", \"12426308\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the serine kinase unknown\", \"Specific serine residues not pinpointed\", \"Physiological role of serine phosphorylation in vivo not tested\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Downstream of STAT6, identification of arginase I as the effector suppressing NO production in macrophages, and demonstration of STAT6 requirement for goblet cell hyperplasia during nematode infection, linked STAT6 to defined anti-inflammatory and mucosal defense programs.\",\n      \"evidence\": \"STAT6-KO macrophages with arginine supplementation rescue; STAT6-KO mice in nematode infection model\",\n      \"pmids\": [\"11160269\", \"11136476\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full repertoire of STAT6-dependent target genes not catalogued\", \"Direct versus indirect transcriptional effects not distinguished genome-wide\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Discovery of p100 as a STAT6 coactivator bridging STAT6 to RNA Pol II, and identification of STAT6-dependent Ym1 promoter elements, began to define the transcription complex architecture at target genes.\",\n      \"evidence\": \"Reciprocal Co-IP and in vitro pulldown for p100-STAT6 and p100-Pol II; EMSA with STAT6-null nuclear extracts on Ym1 promoter\",\n      \"pmids\": [\"12234934\", \"12215441\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether p100 is constitutive or stimulus-recruited was unclear\", \"Genome-wide occupancy of the STAT6-p100 complex not mapped\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Assembly of a ternary STAT6–p100–RNA helicase A complex on IL-4-responsive promoters, and discovery that the PARP-family protein CoaSt6 enhances STAT6 transcription through poly(ADP-ribosyl)ation activity, revealed enzymatic cofactors within the STAT6 transactivation machinery.\",\n      \"evidence\": \"ChIP plus RNAi for RHA; in vitro PARP assay with catalytically inactive CoaSt6 mutant and pharmacological PARP inhibition\",\n      \"pmids\": [\"16914450\", \"17478423\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"ADP-ribosylation substrates beyond p100 not identified\", \"Whether RHA helicase activity is required was not tested\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Live-cell imaging demonstrated that STAT6 constitutively shuttles into the nucleus via the coiled-coil domain and importin-α/β, with cytokine-induced nuclear accumulation resulting from phosphorylation-dependent DNA retention rather than increased import, resolving the mechanism of signal-dependent nuclear concentration.\",\n      \"evidence\": \"FRAP and photobleaching with importin pathway inhibition and domain deletions\",\n      \"pmids\": [\"20498360\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Nuclear export pathway not characterized\", \"Whether other nuclear factors contribute to retention beyond DNA binding was unclear\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Identification of Grail as an E3 ligase mediating STAT6 proteasomal degradation, and demonstration of B-cell-intrinsic STAT6 requirement for germinal center formation via Gpr183/Ebi2 regulation, expanded understanding of both STAT6 turnover and its cell-type-specific functions.\",\n      \"evidence\": \"Co-IP and ubiquitination assay with Grail-KO Th2 cells; conditional B-cell STAT6 KO in helminth infection model with Gpr183 expression analysis\",\n      \"pmids\": [\"25145352\", \"24777733\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Ubiquitin chain linkage type for Grail-mediated degradation not determined\", \"Whether Gpr183 is a direct STAT6 transcriptional target not shown\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"The crystal structure of phosphorylated STAT6 homodimer bound to DNA revealed the structural basis for N4-site selectivity through H415 and a dramatic conformational rearrangement upon DNA binding, providing the first atomic-resolution view of STAT6 target recognition.\",\n      \"evidence\": \"X-ray crystallography, SAXS, molecular dynamics, and H415N mutagenesis with in vitro/in vivo DNA binding\",\n      \"pmids\": [\"27803324\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structure of full-length STAT6 (including TAD) not solved\", \"How coactivators dock onto the DNA-bound dimer not structurally defined\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Structural and functional characterization of the NCOA1–STAT6 interaction, and identification of a stapled peptide that disrupts it and blocks STAT6-dependent transcription, validated NCOA1 as an essential STAT6 coactivator and demonstrated therapeutic targetability.\",\n      \"evidence\": \"Crystal structure of stapled peptide–NCOA1 complex, reporter assay, Co-IP disruption\",\n      \"pmids\": [\"29090910\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether NCOA1 is required at all STAT6 target genes or a subset was not determined\", \"In vivo efficacy of the stapled peptide not tested\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Genome-wide epigenomic profiling revealed that STAT6 actively represses inflammatory enhancers through HDAC3-dependent deacetylation — reducing p300, Pol II, eRNA, H3K27ac, and chromatin accessibility at NF-κB-co-occupied sites — establishing enhancer-level repression as a primary anti-inflammatory mechanism.\",\n      \"evidence\": \"ChIP-seq, ATAC-seq, RNA-seq in WT and STAT6-KO macrophages with HDAC3 inhibition\",\n      \"pmids\": [\"29343442\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How STAT6 recruits HDAC3 (direct interaction or adaptor-mediated) not established\", \"Whether repression is reversible upon STAT6 removal not kinetically resolved\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Discovery that CBP acetylates STAT6 at K383 to suppress M2 polarization (promoted by Trim24-mediated CBP ubiquitination), and that STAT6 induces Gas6 for efferocytosis, revealed acetylation as a suppressive modification and identified a physiological output linking STAT6 to apoptotic cell clearance.\",\n      \"evidence\": \"MS identification of K383 acetylation, Trim24-KO macrophages; STAT6-KO adoptive transfer rescuing efferocytosis with Gas6-expressing macrophages\",\n      \"pmids\": [\"31554795\", \"31363052\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Deacetylase responsible for removing K383 acetylation not identified\", \"Whether Gas6 induction is a direct or indirect STAT6 target not determined\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"TRAF6 was shown to stabilize STAT6 by blocking K48-linked ubiquitination, while STAT6 was also found to inhibit ferroptosis by competing with p53 for CBP binding to restore SLC7A11, revealing non-canonical STAT6 functions in protein stability and cell death pathways.\",\n      \"evidence\": \"TRAF6-KD macrophages with K48/K63 ubiquitin linkage discrimination; STAT6 conditional KO mice with p53 acetylation and SLC7A11 expression assays\",\n      \"pmids\": [\"33017719\", \"35668064\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether TRAF6-STAT6 stabilization is cytokine-dependent or constitutive not fully resolved\", \"Generality of STAT6 anti-ferroptotic function beyond lung epithelium unknown\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Identification of germline gain-of-function STAT6 mutations (E377K, E372K) in the DNA-binding domain causing constitutive nuclear localization, enhanced DNA binding, and severe early-onset allergic disease — reversible by JAK inhibition — established STAT6 as a Mendelian disease gene and validated the clinical relevance of its structural biology.\",\n      \"evidence\": \"Whole-exome sequencing in patients, EMSA, luciferase assays, immunofluorescence, gastric organoids, ruxolitinib rescue\",\n      \"pmids\": [\"36216080\", \"36758835\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full phenotypic spectrum of STAT6 gain-of-function in humans not delineated\", \"Structural mechanism by which DNA-binding domain mutations cause constitutive activation not crystallographically resolved\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"TRAF3 was identified as an E3 ligase ubiquitinating STAT6 at K450 to enhance its transcriptional activity and M2 polarization, while somatic STAT6 gain-of-function mutations in follicular lymphoma were shown to create a self-reinforcing STAT6–PARP14 circuit, linking STAT6 regulation to both innate immunity and lymphomagenesis.\",\n      \"evidence\": \"Quantitative ubiquitomics with K450 mutagenesis and TRAF3-KO mice; ChIP showing STAT6MUT-specific PARP14 promoter binding with PARP inhibitor rescue in pre-B CFU assay\",\n      \"pmids\": [\"37474750\", \"35851155\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Ubiquitin chain type at K450 not fully characterized\", \"Whether PARP14 circuit operates in human follicular lymphoma patients in vivo not confirmed\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the identity of the kinase responsible for STAT6 serine phosphorylation in the TAD, the structural basis of full-length STAT6 interaction with its coactivator complex, the mechanism of HDAC3 recruitment to STAT6-repressed enhancers, and the physiological significance of constitutive STAT6 mitochondrial association.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Serine kinase for TAD phosphorylation unidentified\", \"Full-length STAT6 structure including TAD and coactivator contacts not solved\", \"HDAC3 recruitment mechanism to STAT6 at enhancers not defined\", \"Functional role of STAT6 at mitochondria uncharacterized\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [3, 7, 9, 22, 35, 36]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [2, 5, 7, 13, 14, 24, 29]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [19, 22, 35, 36]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [19]},\n      {\"term_id\": \"GO:0005739\", \"supporting_discovery_ids\": [20]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 1, 3, 8, 18, 35]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [0, 1, 10, 11, 24, 26, 30, 33, 37]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [2, 5, 7, 13, 14, 16, 17, 22, 23, 24]},\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [24, 25]}\n    ],\n    \"complexes\": [\n      \"STAT6-p100-RHA ternary complex\",\n      \"STAT2:STAT6 heterodimer\"\n    ],\n    \"partners\": [\n      \"CBP\",\n      \"NCOA1\",\n      \"TSN\",\n      \"DHX9\",\n      \"TRAF3\",\n      \"TRAF6\",\n      \"RNF128\",\n      \"TIPARP\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}